A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study

The predictive effect of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) treatment is still highly discussed. The primary objective of our study was to investigate a possible prognostic/predictive value of ctDNA under regorafenib treatment. This prospective multicenter translational biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Unseld, Matthias, Belic, Jelena, Pierer, Kerstin, Zhou, Qing, Moser, Tina, Bauer, Raimund, Piringer, Gudrun, Gerger, Armin, Siebenhüner, Alexander, Speicher, Michael, Heitzer, Ellen, Prager, Gerald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894541/
https://www.ncbi.nlm.nih.gov/pubmed/32949150
http://dx.doi.org/10.1002/ijc.33303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894541/
https://www.ncbi.nlm.nih.gov/pubmed/32949150
http://dx.doi.org/10.1002/ijc.33303

Ejemplares similares